Company
About Edgewise
Management Team
Board of Directors
Scientific Advisory Board
R & D
Our Pipeline
Clinical Trials
Areas of Focus
Scientific Presentations & Publications
Patients & Families
Our Promise
Our Research
Clinical Trials
Community & Resources
Investors & News
Corporate Profile
News
Events & Presentations
Analyst Coverage
Stock Information
Stock Quote
Stock Chart
Financials
SEC Filings
Governance
Documents and Charters
Executive Management
Board of Directors
Committee Composition
Resources & FAQs
Investor FAQs
Investor Email Alerts
Investor Contacts
Join Our Team
Contact
Company
About Edgewise
Management Team
Board of Directors
Scientific Advisory Board
R & D
Our Pipeline
Clinical Trials
Areas of Focus
Scientific Presentations & Publications
Patients & Families
Our Promise
Our Research
Clinical Trials
Community & Resources
Investors & News
Corporate Profile
News
Events & Presentations
Analyst Coverage
Stock Information
Stock Quote
Stock Chart
Financials
SEC Filings
Governance
Documents and Charters
Executive Management
Board of Directors
Committee Composition
Resources & FAQs
Investor FAQs
Investor Email Alerts
Investor Contacts
Join Our Team
Contact
Creating lifesaving medicines for rare muscle disorders
our vision
Improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company.
latest news
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
May 13, 2021
READ MORE
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy
May 4, 2021
READ MORE
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
Apr 27, 2021
READ MORE
READ ALL ›
learn about our pipeline
view pipeline
2021 © Copyright. Edgewise Therapeutics. All Rights Reserved.
Privacy Policy
|
Terms of Use
.
